Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events

Journal of Clinical Pharmacology

Volumn 48, Issue 3, 2008, Pages 335-343

  Gengo, Francis M ^a,b,c   Rainka, Michelle ^c   Robson, Matthew ^c   Gengo, Michael F ^c   Forrest, Alan ^b   Hourihane, Maurice ^c   Bates, Vernice ^a,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b Department of Pharmacy Practice ^*  (United States)

^c DENT NEUROLOGIC INSTITUTE   (United States)

Author keywords

Aspirin; Aspirin resistance; Platelet aggregation; Stroke; Stroke prophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; DIPYRIDAMOLE;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PREVALENCE; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; STATISTICAL ANALYSIS; STROKE; SYMPTOM; THROMBOCYTE; THROMBOCYTE AGGREGATION;

AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; COLLAGEN; CORONARY ARTERY DISEASE; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; ODDS RATIO; PLATELET AGGREGATION; RECURRENCE; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT FAILURE;

EID: 39149103679     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007313324     Document Type: Article

References (32)

1. Antithrombotic Trialists Collaboration. Collaborative meta analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br Med J. 2002 ; 324: 71-86.
2. Cattaneo M. Aspirin and clopidogrel: efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004 ; 24: 1980-1987.
3. Buchanan MR, Brister SJ Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol. 1995 ; 11: 221-227.
4. Gum P., Kottke-Marchant K., Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001 ; 88: 230-235.
5. Mueller MR, Salat A., Stangl P., et al. Variable platelet response to low dose aspirin and risk of limb deterioration in patients submitted to peripheral angioplasty. Thromb Haemost. 1997 ; 78: 1003-1007.
6. Grundmann K., Jaschonek K., Kleine B., Dichgans J., Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003 ; 250: 63-66.
7. Andersen K., Hurlen M., Arnesen H., Seljeflot I. Aspirin nonresponsiveness as measured by PFA-100 in patients with coronary artery disease. Thrombosis Res. 2002 ; 108: 37-42.
8. Sane DC, McKee SA, Malinin AI, Serebruany VL Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol. 2002 ; 90: 893-895.
9. Grotemeyer KH, Scharafinski HW, Husstedt IW Two year follow-up of aspirin responder and aspirin nonresponder: a pilot study including 180 post stroke patients. Thromb Res. 1993 ; 71: 397-403.
10. Eikelboom JW, Hirsh J., Weitz JI, Johnston M., Yi Q., Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002 ; 105: 1650-1655.
11. Gum PA, Kottke-Marchant K., Welsh PA, White J., Topol EJ A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003 ; 41: 961-965.
12. Sathiropas P. Detection of small inhibitory effects on acetylsalicylic acid (ASA) by platelet impedance aggregometry in whole blood. Thromb Res. 1988 ; 51: 55-62.
13. Friend M., Vucenik I., Miller M. Platelet responsiveness to aspirin in patients with hyperlipidemia. Br Med J. 2003 ; 326: 83-83.
14. Korpanty A., Ravindra S., Yassin J., Frenkel EP Sensitivity of whole blood aggregation, platelet rich plasma, and platelet function analyzer in detection aspirin effect on platelet function. J Am Soc Hematol. 2002 ; 100: 11.
15. Korpanty A., Frenkel EP, Sarode R. An approach to the assessment of platelet function: comparison of optical platelet rich and impedance whole blood aggregation methods. Thrombosis/ Hemostasis. 2005 ; 11: 25-35.
16. Ivandic B., Giannitis E., Schlick P., Staritz P., Katus H., Hohlfeld T. Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin Chem. 2007 ; 53: 614-619.
17. Berrouschot J., Schwetlick B., von Twickel G., et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand. 2006 ; 113: 31-35.
18. Marcus AJ Eicosanoid interactions between platelets, endothelial cells, and neutrophils. Methods Enzymol. 1990 ; 187: 585-598.
19. Santos MT, Valles J., Marcus AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes: a new approach to platelet activation and recruitment. J Clin Invest. 1991 ; 87: 571-580.
20. D'Andrea G., Perini L., Hasselmark MA, Canazi AR Effect of picotamide on aggregation in patients for cerebral infarction. Functional Neurol. 1995 ; 10: 91-97.
21. Cheng X., Chen P., Ng W., Kwok Y., Lau C. Prevalence of profile predictors and natural history of aspirin resistance in patients with coronary artery disease. Presented at: American Heart Association 6th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke ; May 7-9, 2005 ; Washington, DC.
22. Altman R., Luciardi HL, Muntaner J., et al. The antithrombotic profile of aspirin: aspirin resistance or failure ? Thromb J. 2004 ; 2: 1.
23. Weksler BB Platelet function and antiplatelet agents. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Stroke Pathophysiology, Diagnosis and Management. 3 rd ed. London: Churchill Livingston ; 1998.
24. Martin CP, Talbert RL Aspirin resistance: an evaluation of current evidence and measurement methods. Pharmacotherapy. 2005 ; 25: 942-953.
25. McKee SA, Sane DC, Deliargyris EN Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost. 2002 ; 88: 711-715.
26. Hankey GJ, Eikelboom JW Aspirin resistance. Br Med J. 2004 ; 328: 477-479.
27. Michos ED, Ardehali R., Blumenthal RS, et al. Aspirin and clopidogrel resistance. Mayo Clin Proc. 2006 ; 81: 518-526.
28. Diener HC, Forbes CC, Sivenius J., et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 ; 143: 1-13.
29. Tantry US, Bliden KP, Gurbel PA Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother. 2005 ; 6: 2007-2045.
30. Manoharan A. Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders. Am J Hematol. 2006 ; 81: 676-683.
31. Dorsch MP, Dunn SP Antiplatelet drug resistance: almost ready for prime time. Pharmacotherapy. 2006 ; 26: 1201-1202.
32. Bhatt DL, Flather MD, Hacke W., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral artery disease in the CHARISMA trial. J Am Coll Cardiol. 2007 ; 49: 1982 -1988.